benzoates

Summary

Summary: Salts and esters of BENZOIC ACID that possess antibacterial and antifungal properties. They are used as preservatives in pharmaceuticals, cosmetics, and foods.

Top Publications

  1. ncbi Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial
    Stella Maria G Kyvelou
    Hypertension Unit, 1st Cardiology Department, Athens University, Hippokration Hospital, Greece
    Hellenic J Cardiol 47:21-8. 2006
  2. ncbi Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
  3. ncbi Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression
    Jiu Chang Zhong
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Vascular Biology, Shanghai Institute of Hypertension, Shanghai 200025, China
    Regul Pept 166:90-7. 2011
  4. ncbi Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
    S Yusuf
    Lancet 372:1174-83. 2008
  5. ncbi BenR, a XylS homologue, regulates three different pathways of aromatic acid degradation in Pseudomonas putida
    C E Cowles
    Department of Microbiology, The University of Iowa, Iowa City, Iowa 52242, USA
    J Bacteriol 182:6339-46. 2000
  6. ncbi Constrictor and dilator effects of angiotensin II on cerebral arterioles
    Jean-Martin Vincent
    Laboratoire de Pharmacologie, , , 5 rue Albert Lebrun, 54000 Nancy, France
    Stroke 36:2691-5. 2005
  7. ncbi Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes
    Hirofumi Makino
    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-Okayama, Japan
    Diabetes Care 30:1577-8. 2007
  8. ncbi Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet
    Haiyan Jin
    Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami Kogushi 1 1 1 Ube, Yamaguchi 755 8505, Japan
    Biochem Biophys Res Commun 364:801-7. 2007
  9. ncbi Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
    Stephen C Benson
    Department of Biological Sciences, California State University, Hayward, USA
    Hypertension 43:993-1002. 2004
  10. ncbi Isolation and characterization of novel benzoates, cinnamates, flavonoids, and lignans from Riesling wine and screening for antioxidant activity
    B Baderschneider
    , Schleinitzstrasse 20, DE-38106 Braunschweig, Germany
    J Agric Food Chem 49:2788-98. 2001

Research Grants

  1. OCULAR DISPOSITION OF ACYCLOGUANOSINE ANALOGUES
    Ashim Mitra; Fiscal Year: 2001
  2. OCULAR DISPOSITION OF ACYCLOGUANOSINE ANALOGUES
    Ashim Mitra; Fiscal Year: 1999
  3. ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES
    Michael Rod Zalutsky; Fiscal Year: 2010
  4. BXR SIGNALING IN VERTEBRATE DEVELOPMENT
    Bruce Blumberg; Fiscal Year: 2004
  5. Contingency Management for Initiating Smoking Abstinence
    WILLIAM BARRY WHITE; Fiscal Year: 2010
  6. Contingency Management for Initiating Smoking Abstinence
    William White; Fiscal Year: 2009
  7. WHY DO METABOLIC RISK FACTORS CLUSTER WITH HYPERTENSION?
    Theodore Kurtz; Fiscal Year: 2003
  8. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2003
  9. Imaging of O6-Alkylguanine-DNA Alkyltransferase
    Ganesan Vaidyanathan; Fiscal Year: 2005
  10. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2006

Detail Information

Publications184 found, 100 shown here

  1. ncbi Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial
    Stella Maria G Kyvelou
    Hypertension Unit, 1st Cardiology Department, Athens University, Hippokration Hospital, Greece
    Hellenic J Cardiol 47:21-8. 2006
    ..This study was conducted to evaluate blood pressure control and the plasma lipid profile in hypertensive patients after six months' treatment with ARB...
  2. ncbi Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
    ..We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes...
  3. ncbi Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression
    Jiu Chang Zhong
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Vascular Biology, Shanghai Institute of Hypertension, Shanghai 200025, China
    Regul Pept 166:90-7. 2011
    ..In conclusion, telmisartan treatment attenuates vascular hypertrophy in SHR by the modulation of ACE2 and profilin-1 expression with a marked reversal of ERK1/2 and JNK phosphorylation signaling pathways...
  4. ncbi Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
    S Yusuf
    Lancet 372:1174-83. 2008
    ..FUNDING: Boehringer Ingelheim...
  5. ncbi BenR, a XylS homologue, regulates three different pathways of aromatic acid degradation in Pseudomonas putida
    C E Cowles
    Department of Microbiology, The University of Iowa, Iowa City, Iowa 52242, USA
    J Bacteriol 182:6339-46. 2000
    ..The action of BenR in repressing 4-HBA uptake is probably indirect...
  6. ncbi Constrictor and dilator effects of angiotensin II on cerebral arterioles
    Jean-Martin Vincent
    Laboratoire de Pharmacologie, , , 5 rue Albert Lebrun, 54000 Nancy, France
    Stroke 36:2691-5. 2005
    ....
  7. ncbi Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes
    Hirofumi Makino
    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-Okayama, Japan
    Diabetes Care 30:1577-8. 2007
  8. ncbi Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet
    Haiyan Jin
    Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Minami Kogushi 1 1 1 Ube, Yamaguchi 755 8505, Japan
    Biochem Biophys Res Commun 364:801-7. 2007
    ..Tel inhibited HSCs activation and proliferation. These results suggested that Tel could be a promising drug for NASH related liver fibrosis...
  9. ncbi Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
    Stephen C Benson
    Department of Biological Sciences, California State University, Hayward, USA
    Hypertension 43:993-1002. 2004
    ....
  10. ncbi Isolation and characterization of novel benzoates, cinnamates, flavonoids, and lignans from Riesling wine and screening for antioxidant activity
    B Baderschneider
    , Schleinitzstrasse 20, DE-38106 Braunschweig, Germany
    J Agric Food Chem 49:2788-98. 2001
    ..Structural elucidation of the newly isolated wine constituents is reported together with the determination of their antioxidant activity...
  11. ncbi [An experimental study of expression of angiotension converting enzyme 2 in myocardium and effect of telmisartan treatment in pressure-overloaded rats]
    Li Jun Wang
    Department of Cardiology, The Affiliated Baoan Hospital of Nanfang Medical University, Shenzhen 518101, Guangdong, China
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 20:218-22. 2008
    ..To study the effect of hypertension and telmisartan treatment on the protein and gene expression of cardiac angiotensin-converting enzyme 2 (ACE2) in pressure-overloaded rats...
  12. ncbi Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action
    Arun Prasath Lakshmanan
    Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City, Japan
    Free Radic Res 45:575-84. 2011
    ..These findings suggest that Ang-II plays a significant role in DN and telmisartan would be beneficial in reducing oxidative stress and fibrosis in STZ-induced DN...
  13. ncbi Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue
    Hiroshi Kudo
    Third Department of Internal Medicine, University of Toyama, Toyama, Japan
    Liver Int 29:988-96. 2009
    ..The aim of this study was to investigate the efficacy and mechanisms of Tel on a murine NASH model...
  14. ncbi Molecular cloning and functional characterization of the genes encoding benzoate and p-hydroxybenzoate degradation by the halophilic Chromohalobacter sp. strain HS-2
    Dockyu Kim
    Department of Environmental Engineering, BK21 Team for Biohydrogen Production, Chosun University, Gwangju, Korea
    FEMS Microbiol Lett 280:235-41. 2008
    ..When expressed in Escherichia coli, benzoate 1,2-dioxygenase (BenABC) and p-hydroxybenzoate hydroxylase (PobA) transformed benzoate and p-hydroxybenzoate into cis-benzoate dihydrodiol and protocatechuate, respectively...
  15. ncbi Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy
    Vijayakumar Sukumaran
    Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan
    Hypertens Res 33:695-702. 2010
    ..Our results indicate that telmisartan treatment significantly improved LV function and ameliorated the progression of cardiac remodeling in rats with CHF after EAM...
  16. ncbi Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress
    Vijayakumar Sukumaran
    Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan
    Eur J Pharmacol 652:126-35. 2011
    ....
  17. ncbi Arabidopsis GH3.12 (PBS3) conjugates amino acids to 4-substituted benzoates and is inhibited by salicylate
    Rachel A Okrent
    Department of Plant and Microbial Biology, University of California, Berkeley, California 94720 3102, USA
    J Biol Chem 284:9742-54. 2009
    ..We found PBS3 favors 4-substituted benzoates such as 4-aminobenzoate and 4-hydroxybenzoate, with moderate activity on benzoate and no observed activity with ..
  18. ncbi Angiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generation
    S Amano
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Int J Tissue React 25:51-5. 2003
    ....
  19. ncbi The target for the Pseudomonas putida Crc global regulator in the benzoate degradation pathway is the BenR transcriptional regulator
    Renata Moreno
    Departamento de Biotecnologia Microbiana, Centro Nacional de Biotecnologia, CSIC, Campus de la Universidad Autonoma de Madrid, Cantoblanco, 28049 Madrid, Spain
    J Bacteriol 190:1539-45. 2008
    ....
  20. ncbi Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma
    Daniel Walcher
    Department of Internal Medicine II Cardiology, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    Hypertension 51:259-66. 2008
    ..These data provide a novel mechanism to explain how telmisartan modulates lymphocyte activation by its PPARgamma-activating properties...
  21. ncbi Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study
    D Galzerano
    Department of Cardiology, San Gennaro Hospital, Naples, Italy
    J Hum Hypertens 18:53-9. 2004
    ..In conclusion, telmisartan 80 mg was well tolerated and significantly reduced SBP, DBP and LVMI after 12 months' treatment compared with HCTZ...
  22. ncbi Telmisartan/Hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension
    Joel M Neutel
    Orange County Research Center, Tustin, USA
    Hypertens Res 28:555-63. 2005
    ..5 during the last 6 h of the 24-h dosing interval, which corresponds to the high-risk early-morning hours, and that T80/H12.5 provided additional blood pressure reductions...
  23. ncbi Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, Connecticut, USA
    Blood Press Monit 13:21-7. 2008
    ..Both studies support the strategy of using angiotensin receptor blockers with a higher dose of a thazide diuretic (25 mg) for enhancing the control of hypertension...
  24. ncbi Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension
    Caroline Fenton
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:2013-26; discussion 2027-8. 2003
    ..In clinical trials of up to 4 years, including elderly patients, telmisartan/HCTZ had similar tolerability to placebo, with few reports of hypokalaemia. Most adverse events were mild to moderate...
  25. ncbi Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements
    Takuya Nishimura
    Department of Clinical Pharmacology and Therapeutics, Tohoku University School of Pharmaceutical Science and Medicine, Sendai, Japan
    Clin Exp Hypertens 27:477-89. 2005
    ..Losartan, 25 mg a day, which is usually used as an initial dose in Japan, is apparently insufficient to obtain adequate antihypertensive effect and sufficient duration of action...
  26. ncbi Characterization of anaerobic catabolism of p-coumarate in Rhodopseudomonas palustris by integrating transcriptomics and quantitative proteomics
    Chongle Pan
    Chemical Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
    Mol Cell Proteomics 7:938-48. 2008
    ..The integrated gene expression data provided strong support for the non-beta-oxidation route in R. palustris. A putative gene was proposed for every step in the non-beta-oxidation route...
  27. ncbi Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers
    H Kakuta
    Pharmacology Laboratory, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co, Ltd, Tsukuba, Japan
    Int J Clin Pharmacol Res 25:41-6. 2005
    ..The present findings suggest that telmisartan (Micardis) may have long-lasting blood pressure-lowering effects and superior cardioprotective properties in patients with hypertension due to its strongest AT1 receptor antagonistic ability...
  28. ncbi Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension
    Ralf A Benndorf
    Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital Hamburg Eppendorf, D 20246 Hamburg, Germany
    Metabolism 55:1159-64. 2006
    ..Future studies will demonstrate whether these telmisartan-induced effects may contribute to a blood pressure-independent reduction in cardiovascular morbidity...
  29. ncbi Possible beneficial effect of telmisartan on glycemic control in diabetic subjects
    Sachiko Honjo
    Diabetes Care 28:498. 2005
  30. ncbi Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension
    Haruhito Uchida
    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Japan
    Hypertens Res 27:545-50. 2004
    ..In conclusion, telmisartan 40 mg/day was found to be effective for reducing MHBP and arterial wall stiffness in patients with mild-to-moderate hypertension, and thus may also be effective for improving cerebrocardiovascular mortality...
  31. ncbi Study of factors which negatively affect expression of the phenol degradation operon pheBA in Pseudomonas putida
    Marta Putrins
    Department of Genetics, Institute of Molecular and Cell Biology, Tartu University and Estonian Biocentre, 51010 Tartu, Estonia
    Microbiology 153:1860-71. 2007
    ....
  32. ncbi Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences
    Yoshitaka Miura
    Diabetes Care 28:757-8. 2005
  33. ncbi The pimFABCDE operon from Rhodopseudomonas palustris mediates dicarboxylic acid degradation and participates in anaerobic benzoate degradation
    Faith H Harrison
    Department of Microbiology, The University of Iowa, 3-450 BSB, Iowa City, IA 52242, USA
    Microbiology 151:727-36. 2005
    ..However, the finding that the pim operon deletion mutant is still able to grow on dicarboxylic acids, albeit at a slower rate, indicates that R. palustris has additional genes that can also specify the degradation of these compounds...
  34. ncbi Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmi
    Koon Teo
    McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5
    Am Heart J 148:52-61. 2004
    ..Baseline patient characteristics are comparable to the Heart Outcomes Prevention Evaluation (HOPE) trial, the basis of the design of the current study, confirming that patients are at high-risk...
  35. ncbi Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients
    R Fogari
    Department of Internal Medicine and Therapeutics, Clinica Medica II, IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy
    J Hum Hypertens 20:177-85. 2006
    ....
  36. ncbi Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo
    Athanasios J Manolis
    Txanio General Hospital, Piraeus, Greece
    J Hypertens 22:1033-7. 2004
    ..5 mg, and are well tolerated, in lowering systolic blood pressure (SBP) in patients with isolated systolic hypertension (ISH)...
  37. ncbi Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders
    Sho ichi Yamagishi
    Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume 830 0011, Japan
    Curr Mol Med 7:463-9. 2007
    ..In this paper, we reviewed the potential utility of telmisartan in insulin resistance and vascular complications in diabetes...
  38. ncbi Interaction between glutamatergic and nitrergic mechanisms mediating cardiovascular responses to L-glutamate injection in the diagonal band of Broca in anesthetized rats
    Rodrigo Fiacadori Tavares
    Department of Pharmacology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Av Bandeirantes, 3900, CEP 14090 090, Brazil
    Life Sci 81:855-62. 2007
    ..These results suggest that the microinjection of L-glu into the dbB of urethane-anesthetized rats causes dose-related depressor and bradycardiac responses through the NMDA receptor-NO-guanylate cyclase pathway...
  39. ncbi Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients
    Adamasco Cupisti
    Nephrology Unit, Department of Internal Medicine, University of Pisa, Via Roma 67, 56100, Pisa, Italy
    Biomed Pharmacother 57:169-72. 2003
    ....
  40. ncbi Exo1: a new chemical inhibitor of the exocytic pathway
    Yan Feng
    Institute of Chemistry and Cell Biology, Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:6469-74. 2003
    ..Thus, Exo1 allows the fatty acid exchange activity of Bars50 to be distinguished from ARF1 activity in the control of Golgi tubulation...
  41. ncbi A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring
    Yves Lacourciere
    Hypertension Research Unit, CHUL, Centre Hospitalier Universitaire de Quebec, 2705 boulevard Laurier S 135, Sainte Foy, Quebec, QC G1V 4G2, Canada
    Am J Hypertens 19:104-12. 2006
    ....
  42. ncbi BadM is a transcriptional repressor and one of three regulators that control benzoyl coenzyme A reductase gene expression in Rhodopseudomonas palustris
    Caroline M Peres
    Department of Microbiology, Box 357242, 1959 N E Pacific Street, University of Washington, Seattle, WA 98195 7242, USA
    J Bacteriol 188:8662-5. 2006
    ..BadM controls gene expression from the benzoyl-CoA reductase promoter in concert with two previously described transcriptional activators...
  43. ncbi Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    J Clin Hypertens (Greenwich) 8:626-33. 2006
    ..These data support using a higher dose of a thiazide diuretic (25 mg) with a long-acting angiotensin receptor blocker as a useful strategy for improving hypertension control...
  44. ncbi Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice
    H Nagai
    Department of Pharmacology, Gifu Pharmaceutical University, Gifu, Japan
    Pharmacology 58:101-12. 1999
    ..These findings suggest that the inhibitory effect of Am-80 on CIA is partially by modulating the production of the proinflammatory cytokine, IL-6...
  45. ncbi Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE
    Hans Christoph Diener
    Department of Neurology, University of Duisburg Essen, Essen, Germany
    Lancet Neurol 7:875-84. 2008
    ..The putative neuroprotective effects of antiplatelet compounds and the angiotensin II receptor antagonist telmisartan were investigated in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial...
  46. ncbi Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan
    Markus Clemenz
    Center for Cardiovascular Research, Institute of Pharmacology, Charite Universitatsmedizin Berlin, Hessische Str 3 4, 10115 Berlin, Germany
    Diabetes 57:1405-13. 2008
    ..Activation of the PPARalpha ligand binding domain (LBD) was investigated using transactivation assays...
  47. ncbi Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study
    Steen Neldam
    Rodøvre Centrum, Denmark
    Am J Geriatr Cardiol 15:151-60. 2006
    ..0175). Adverse events (41.2% and 53.7%, respectively) and discontinuations (5.0% and 11.3%, respectively) were lower (p<0.0001) with telmisartan than with amlodipine, mainly due to peripheral edema (1.2% and 24.3%, respectively)...
  48. ncbi Haemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteers
    Noreen M Vingerhoedt
    Department of Clinical Pharmacology, St. George Hospital, Kogarah, 2217, Australia
    J Renin Angiotensin Aldosterone Syst 4:244-8. 2003
    ..CONCLUSIONS: Telmisartan effectively blocked the effects of intravenous Ang II on CI, BP, RI and SI in healthy volunteers. Changes in CI make a major contribution to increase in BP response to intravenous Ang II in normal volunteers...
  49. ncbi Are the pleiotropic effects of telmisartan clinically relevant?
    C V Rizos
    Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece
    Curr Pharm Des 15:2815-32. 2009
    ..However, do all these pleiotropic effects translate into clinical benefit? Recent studies have tried to answer this question with promising but not definitive results...
  50. ncbi Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs
    Raphaelle Brody
    Hypertension Unit, The Chaim Sheba Medical Center, Tel Hashomer, Israel
    Am J Hypertens 22:1126-9. 2009
    ..The aim of this study was to evaluate the effect of various antihypertensive drugs on the production and secretion of adiponectin from adipocytes...
  51. ncbi Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment
    Paolo Verdecchia
    McMaster University, Population Health Research Institute, 237 Barton St E, Hamilton, ON L8L2X2 Canada
    Circulation 120:1380-9. 2009
    ..Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown...
  52. ncbi Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension
    J B McGill
    Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA
    Clin Cardiol 24:66-72. 2001
    ..CONCLUSIONS: Telmisartan 80 mg combined with HCTZ 12.5 mg is effective and well tolerated in black patients with mild to moderate hypertension, providing greater antihypertensive activity than the corresponding monotherapies...
  53. ncbi ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study
    Rainer H Boger
    Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg Eppendorf, Germany
    Vasc Med 10:S97-102. 2005
    ....
  54. ncbi Telmisartan: a review of its use in the management of hypertension
    Anna J Battershill
    Adis International Limited, Auckland, New Zealand
    Drugs 66:51-83. 2006
    ....
  55. ncbi Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    Am Heart J 151:176-84. 2006
    ..Therefore, we used ambulatory blood pressure monitoring (ABPM), an automated and objective measure of blood pressure (BP) to overcome these shortcomings in a large community-based trial...
  56. ncbi Exposure to indoor pesticides during pregnancy in a multiethnic, urban cohort
    Gertrud S Berkowitz
    Department of Community and Preventive Medicine, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Environ Health Perspect 111:79-84. 2003
    ..These data underscore the need to assess the potentially adverse effects of pesticide exposure on fetuses and infants and the importance of finding alternative methods for pest management to reduce pesticide exposures...
  57. ncbi Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge
    J Stangier
    Boehringer Ingelheim Pharma KG, Biberach, Germany, and Pharma Bio-Research International B.V, Zuidlaren, The Netherlands
    J Cardiovasc Pharmacol 38:672-85. 2001
    ..In conclusion, telmisartan 40 mg provides rapid-onset, well-tolerated, and near-maximal inhibition of angiotensin II-induced hypertension, with maintenance of the inhibitory effect for 48 h...
  58. ncbi Effect of telmisartan on angiotensin II-mediated collagen gel contraction by adult rat cardiac fibroblasts
    P J Lijnen
    Department of Molecular and Cardiovascular Research, Faculty of Medicine, University of Leuven Katholieke Universiteit Leuven, Belgium
    J Cardiovasc Pharmacol 38:39-48. 2001
    ....
  59. ncbi Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation
    Toshihide Kurihara
    Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan
    Invest Ophthalmol Vis Sci 47:5545-52. 2006
    ..Treatment with the AT1R blocker telmisartan efficiently prevented these signs of retinal neural damage through the reduction of local angiotensin II expression, the blockade of AT1R, and the relative upregulation of AT2R function...
  60. ncbi Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats
    Naohiko Kobayashi
    Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan
    Am J Hypertens 21:576-81. 2008
    ....
  61. ncbi Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy
    George Bakris
    Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
    Kidney Int 74:364-9. 2008
    ..We conclude that telmisartan is superior to losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, despite a similar reduction in blood pressure...
  62. ncbi In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist
    Marc P Maillard
    Division of Hypertension and Vascular Medicine, University Hospital of Lausanne, CHUV CH 1011 Lausanne, Switzerland
    J Pharmacol Exp Ther 302:1089-95. 2002
    ..Taken together, our in vitro data show that the insurmountable antagonism of telmisartan is due at least in part to its very slow dissociation from AT1 receptors...
  63. ncbi The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study
    Turgay Celik
    Department of Cardiology, Gulhane Military Medical Academy, Etlik, Ankara, Turkey
    Clin Cardiol 28:298-302. 2005
    ..Angiotensin II receptor blockers (AARBs) and angiotensin-converting enzyme inhibitors (ACEIs) have beneficial effects on atrial conduction times. However, there are not enough data about the comparative effects of those drugs on PWD...
  64. ncbi A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours
    Philippe Gosse
    Service de Cardiologie Hypertension art6éielle, Hôpital Saint André, Bordeaux, France
    Vasc Health Risk Manag 2:195-201. 2006
    ..This supposition is being tested in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) programme...
  65. ncbi Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients
    Isao Usui
    The First Department of Internal Medicine, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930 0194, Japan
    Diabetes Res Clin Pract 77:210-4. 2007
    ..In conclusion, Telmisartan improved insulin resistance with increased serum leptin level in hypertensive and type 2 diabetic patients...
  66. ncbi Effects of telmisartan on fat distribution in individuals with the metabolic syndrome
    Michio Shimabukuro
    Second Department of Internal Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa and Diabetes and Life style Related Disease Center, Tomishiro Chuo Hospital, Okinawa, Japan
    J Hypertens 25:841-8. 2007
    ..Telmisartan, an angiotensin II type 1 receptor blocker, has partial agonistic properties for peroxisome proliferator-activated receptor gamma, which is a key regulator of adipocyte differentiation and function...
  67. ncbi Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone
    G Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
    J Clin Pharm Ther 32:261-8. 2007
    ..The aim of our study was to investigate the metabolic effects of telmisartan and irbesartan in diabetic subjects treated with rosiglitazone...
  68. ncbi Mobilization of putative high-proliferative-potential endothelial colony-forming cells during antihypertensive treatment in patients with essential hypertension
    Ralf A Benndorf
    Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Clinical Pharmacology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Stem Cells Dev 16:329-38. 2007
    ....
  69. ncbi Effect of telmisartan on cholesterol levels in patients with hypertension - Saga Telmisartan Aggressive Research (STAR)
    T Inoue
    Department of Cardiovascular and Renal Medicine, Saga University Faculty of Medicine, Saga, Japan
    Horm Metab Res 39:372-6. 2007
    ..The profound effect of telmisartan to lower cholesterol suggests a potential use in hypertensive patients with dyslipidemia...
  70. ncbi Prevention of stroke in patients with hypertension
    Bjorn Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Am J Cardiol 100:17J-24J. 2007
    ..This will be investigated in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) study...
  71. ncbi Telmisartan in the treatment of hypertension
    Barbara H Rosario
    Sheffield Teaching Hospitals NHS Foundation Trust, Department of Geriatric Medicine, Sir Robert Hadfield Wing, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK
    Expert Opin Drug Metab Toxicol 4:485-92. 2008
    ..Telmisartan is an orally active angiotensin II receptor antagonist prescribed once daily...
  72. ncbi Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension
    Gui Lin Xi
    Center for New Drug Evaluation, Second Military Medical University, Shanghai, China
    Am J Hypertens 21:546-52. 2008
    ..Hypertension is a major risk factor for cardiovascular disease, and data regarding the efficacy and tolerability of telmisartan compared with losartan on blood pressure (BP) control in patients with hypertension...
  73. ncbi ONTARGET: questions asked, questions answered
    Michael A Weber
    J Clin Hypertens (Greenwich) 10:427-30. 2008
  74. ncbi [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction]
    Peter M Nilsson
    , Universitetssjukhuset MAS, Malm
    Lakartidningen 105:1382-4. 2008
  75. ncbi [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study]
    M Burnier
    , CHUV Lausanne
    Praxis (Bern 1994) 97:559-62. 2008
  76. ncbi Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro
    Satoru Yamada
    Department of Internal Medicine, Kitasato Institute Hospital, Tokyo, Japan
    Hypertens Res 31:601-6. 2008
    ..5-fold by telmisartan in 3T3-L1 adipocytes. Our findings suggest that telmisartan may have beneficial effects in type 2 diabetes beyond its antihypertensive effect...
  77. ncbi Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome
    Tatsuya Sasaki
    Cardiovascular Division, Osaka Minami Medical Center, National Hospital Organization, Kawachinagano, Japan
    Hypertens Res 31:921-9. 2008
    ....
  78. ncbi Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study
    Akhilesh Sharma
    Medical Services Department, Glenmark Pharmaceuticals Ltd, Mumbai
    J Indian Med Assoc 106:191-4, 196. 2008
    ..2%). Results of the present study indicate that the FDC of telmisartan+ramipril brings about significant reductions in the systolic and diastolic blood pressure as well as urine albumin excretion...
  79. ncbi Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: an evaluation using the cardio-ankle vascular index (CAVI)
    G Uehara
    Department of Internal Medicine, Takeda Clinic, Kanagawa, Japan
    J Int Med Res 36:1094-102. 2008
    ..We conclude that candesartan is a potentially useful therapy against arterial stiffness in hypertensive patients with type 2 diabetes mellitus...
  80. ncbi Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats
    Binhui Liang
    From the Hypertension Unit, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
    J Cardiovasc Pharmacol 51:457-66. 2008
    ..In Dahl S rats, AT1-receptor stimulation seems to play a critical role in salt-induced hypertension and fibrosis, but a lesser role in tissue hypertrophy...
  81. ncbi Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats
    Shinji Takai
    Department of Pharmacology, Osaka Medical College, Takatsuki, Japan
    Hypertens Res 30:1231-7. 2007
    ..In conclusion, the partial PPARgamma agonist telmisartan might inhibit vascular ACE activity, and result in the prevention of oxidative stress and endothelial dysfunction more effectively than non-agonistic valsartan...
  82. ncbi Rationale for double renin-angiotensin-aldosterone system blockade
    Thomas Unger
    Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, Berlin, Germany
    Am J Cardiol 100:25J-31J. 2007
    ..The benefits of this approach with telmisartan are being investigated in clinical trials, such as the Ongoing Telmisartan Alone in Combination with Ramipril Global Endpoint Trial (ONTARGET)...
  83. ncbi [New therapeutic targets for ACE inhibitors and angiotensin receptor blockers]
    Paweł Petkow-Dimitrow
    II Klinika Kardiologii, Collegium Medicum Uniwersytetu Jagiellońskiego, Krakow
    Pol Arch Med Wewn 117:44-50. 2007
    ..This study is focused on the effect of double blockage (ramipril and telmisartan) on reduction of the occurrence of myocardial infarction, stroke, and heart failure...
  84. ncbi Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism
    Firas Younis
    Department of Physiology and Pharmacology, Hypertension Research Unit, Sackler School of Medicine, Tel Aviv University, Aviv, Israel
    Clin Exp Hypertens 29:419-26. 2007
    ..Blood glucose levels fell rapidly in the treated animals and remained steady in controls. Results indicate that telmisartan is a prototype of a new approach to treating coexisting diabetes and hypertension...
  85. ncbi Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors
    Bernhard Gremmler
    Department of Cardiology, Marienhospital, Bottrop, Germany
    Acta Cardiol 62:321-8. 2007
    ..The efficacy of ACE-inhibitors and beta blockers is well documented in the therapy of heart failure. As pharmacological mechanisms of ATI-receptor-antagonists differ, an additional positive effect can be expected when combining these drugs...
  86. ncbi [Observational study of an AT1-antagonist]
    R K Klocke
    St. Marienhospital Vechta, Marienstr. 6-8, D-49377 Vechta
    MMW Fortschr Med 149:37. 2007
  87. ncbi Telmisartan improves endothelial function in patients with essential hypertension
    Ralf A Benndorf
    Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Medical Center, Hamburg Eppendorf, Germany
    J Cardiovasc Pharmacol 50:367-71. 2007
    ..We therefore investigated whether the new ARB telmisartan improves endothelial function and renal vascular resistance in patients with essential hypertension...
  88. ncbi Plasma renin activity for predicting antihypertensive drug efficacy
    Jon D Blumenfeld
    Am J Hypertens 21:5-6. 2008
  89. ncbi Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension
    Steen Neldam
    Rødovre Centrum, Denmark
    J Clin Hypertens (Greenwich) 10:612-8. 2008
    ..Hypokalemia was rare. These results show that higher-dose thiazide diuretic in combination with T80 in patients with hypertension uncontrolled by T80/H12.5 provides additional blood pressure reductions and is well tolerated...
  90. ncbi Clinical trial update: focus on the ONTARGET study
    David Fitchett
    Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Vasc Health Risk Manag 3:901-8. 2007
    ..Although it is possible that enhanced benefits will be observed with dual therapy, the outcomes with ARB monotherapy remain uncertain...
  91. ncbi Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension
    Shiho Nakayama
    Department of Medicine, Metabolism, and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan
    Hypertens Res 31:7-13. 2008
    ..Our results indicate that olmesartan has more potent arterial blood pressure lowering and anti-inflammatory effects than telmisartan...
  92. ncbi [Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology]
    Gábor Winkler
    Fóvárosi Szent János Kórház II Belosztály
    Orv Hetil 144:1763-8. 2003
    ....
  93. ncbi Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients
    I Petrovic
    Clinical Centre Studenica, Cardiology Department, Kraljevo, Serbia and Montenegro
    J Int Med Res 33:39A-49A. 2005
    ..In conclusion, treatment with telmisartan or ramipril for 6 months resulted in regression of LVH and vascular remodelling. When a combination of telmisartan and ramipril was administered, additional regression and remodelling occurred...
  94. ncbi Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance
    Shinji Makita
    Department of Internal Medicine II and Memorial Heart Center, Iwate Medical University School of Medicine, Morioka 0208505, Japan
    Metabolism 57:1473-8. 2008
    ..Candesartan did not achieve similar improvements in these patients. Among ARBs, telmisartan may have a larger impact on obesity-related diseases that can lead to cardiovascular disorders...
  95. ncbi The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial
    Liffert Vogt
    Department of Clinical Pharmacology and Internal Medicine, Division of Nephrology, University Medical Center, University of Groningen, The Netherlands
    J Hypertens 23:2055-61. 2005
    ....
  96. ncbi Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients
    Maria Karas
    , Canada
    J Hypertens 23:1251-60. 2005
    ..In contrast, the therapy with telmisartan significantly increased parasympathetic activity without changes in NE during the night and day. The therapy with ramipril increased the parasympathetic activity only during the day...
  97. ncbi The ONTARGET/TRANSCEND Trial Programme: baseline data
    P Sleight
    Department of Cardiovascular Medicine, Level 5, John Radcliffe Hospital University of Oxford, UK
    Acta Diabetol 42:S50-6. 2005
    ..These trials are the largest comparisons to date of ARB and ACE-inhibitor therapy in high-risk patients with controlled blood pressure, and the results will contribute significantly to the future treatment of cardiovascular disease...
  98. ncbi Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives
    Maxime Lamarre-Cliche
    Institut de recherches cliniques de Montreal IRCM, Canada
    Am J Hypertens 18:56-64. 2005
    ..This study, part of a clinical trial, was designed to measure the influence of circadian rhythms, antihypertensive drugs, and body posture on plasma renin, on aldosterone, and on their interrelation...
  99. ncbi Intraindividual blood pressure responses to angiotensin-converting enzyme inhibition and angiotensin receptor blockade
    George S Stergiou
    Hypertension Center, Third University Department of Medicine, Sotiria Hospital, 152 Mesogion Avenue, Athens 11527, Greece
    J Clin Hypertens (Greenwich) 7:18-23. 2005
    ..It appears that there are differences in the antihypertensive action of angiotensin-converting enzyme inhibitors and ARBs that may be clinically important...
  100. ncbi Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property
    S Yamagishi
    Department of Medicine, Kurume University School of Medicine, Kurume, Japan
    Med Hypotheses 64:476-8. 2005
    ....
  101. ncbi Comparative effects of telmisartan in the treatment of hypertension
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT 06030-3940, USA
    J Clin Hypertens (Greenwich) 4:20-5. 2002
    ....

Research Grants101 found, 100 shown here

  1. OCULAR DISPOSITION OF ACYCLOGUANOSINE ANALOGUES
    Ashim Mitra; Fiscal Year: 2001
    ..2) branched chain aliphatic esters: pivaloate, isobutyrate, 3) aromatic esters: benzoate, p- methoxy, p-nitro benzoates and 4) alicyclic ester: 1-adamantoate...
  2. OCULAR DISPOSITION OF ACYCLOGUANOSINE ANALOGUES
    Ashim Mitra; Fiscal Year: 1999
    ..2) branched chain aliphatic esters: pivaloate, isobutyrate, 3) aromatic esters: benzoate, p methoxy, p-nitro benzoates and 4) alicyclic ester: 1-adamantoate...
  3. ASTATINE AND IODINE RADIOLABELED MONOCLONAL ANTIBODIES
    Michael Rod Zalutsky; Fiscal Year: 2010
    ..Our studies revealed that radio iodination of anti-EGFRvIII mAbs using reagents containing benzoates bearing charged substituent's or D-amino acid peptides significantly improved retention of radioactivity in ..
  4. BXR SIGNALING IN VERTEBRATE DEVELOPMENT
    Bruce Blumberg; Fiscal Year: 2004
    ..isolated and characterized a novel nuclear receptor activated by a class of endogenous substituted alkyl benzoates. These compounds comprise a novel class of hormone receptor ligand and are related the B-complex vitamins p-..
  5. Contingency Management for Initiating Smoking Abstinence
    WILLIAM BARRY WHITE; Fiscal Year: 2010
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
  6. Contingency Management for Initiating Smoking Abstinence
    William White; Fiscal Year: 2009
    ..Clinic and 24-hour blood pressure (BP) and heart rate (HR) will be additional outcomes. We expect that BP and HR will decrease more among CM than non-CM patients and reductions in smoking may mediate decreases in these indices. ..
  7. WHY DO METABOLIC RISK FACTORS CLUSTER WITH HYPERTENSION?
    Theodore Kurtz; Fiscal Year: 2003
    ....
  8. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2003
    ..Under this alternative hypothesis, the results of the cDNA microarray analysis will be used to identify potential downstream target genes whose expression is altered by the primary genetic defect on chromosome 1. ..
  9. Imaging of O6-Alkylguanine-DNA Alkyltransferase
    Ganesan Vaidyanathan; Fiscal Year: 2005
    ..In summary, this proposal seeks to determine whether the development of a suitable agent for the imaging of tumor AGT will facilitate chemotherapy planning, thereby improving the outcome of alkylator chemotherapy. ..
  10. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2006
    ..Hypertension candidate genes will then be isolated using cDNA screening techniques to identify genes expressed in the brain, adrenal gland, or kidney that map within this chromosome region. ..
  11. IMPROVED PREVENTIVE/RESTORATIVE RESINS AND COMPOSITES
    SABINE DICKENS; Fiscal Year: 2006
    ..The data gathered in these experiments will serve to support a larger R01 grant application with the long-term objectives of developing improved durable materials for adhesives and adhesive composites. ..
  12. REMINERALIZING PULP-CAPPING CEMENTS & BONDING AGENTS
    SABINE DICKENS; Fiscal Year: 2003
    ..The proposed studies will also provide a valuable comparison of in vivo test results to pulp cell response in vitro. ..
  13. KIDNEY SPECIFIC GENE TRANSFER IN HYPERTENSION
    Theodore Kurtz; Fiscal Year: 1999
    ....
  14. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore W Kurtz; Fiscal Year: 2010
    ..This project is designed to investigate genetic factors that influence the development of the metabolic syndrome and ultimately help identify new targets for prevention and treatment of diabetes and cardiovascular disease. ..
  15. NEW EXPERIMENTAL MODELS OF HYPERTENSION
    Theodore Kurtz; Fiscal Year: 2001
    ..Finally, they will distribute these strains to other investigators also interested in studying pathophysiologic mechanisms whereby selected chromosome regions may influence cardiovascular function and BP. ..
  16. MIBG ANALOGUE RADIOPHARMACEUTICALS
    Ganesan Vaidyanathan; Fiscal Year: 2001
    ..Strategies to augment tumor-to-normal tissue ratios will be investigated. The outcome of this study should help improve the endoradiotherapy of neuroendocrine tumors and possibly of medulloblastoma. ..
  17. RESIN-BASED REMINERALIZING CEMENTS AND COMPOSITES
    SABINE DICKENS; Fiscal Year: 2009
    ..Completion of this research will lead to Ca- PO4 cements and composites with improved adhesion to dentin and improved strength for ART and the treatment of root caries. ..
  18. Flavoenzymes in Pyrimidine Metabolism
    Bruce A Palfey; Fiscal Year: 2010
    ..Our studies of the rates of the chemical reactions will identify important parts of the proteins, how they move during reactions, how they speed the synthesis of products, and how these reactions might be blocked. ..
  19. Bisphenol A and Phthalate Exposure in Relation to Fetal Growth and Preterm Birth
    John D Meeker; Fiscal Year: 2010
    ....
  20. TGF-beta and axis formation in Helobdella, a lophotrochozoan
    DAVID WEISBLAT; Fiscal Year: 2007
    ..They will also contribute to understanding the cellular processes known as epithelial-to-mesenchymal transitions (EMTs), which play a critical role both in normal development and in cancer metastasis. ..
  21. ANALYSIS OF PAIR OF RULE GENES IN SEQUENTIAL SEGMENTATIO
    DAVID WEISBLAT; Fiscal Year: 2003
    ..abstract_text> ..
  22. TGF-beta and axis formation in Helobdella, a lophotrochozoan
    David A Weisblat; Fiscal Year: 2010
    ..They will also contribute to understanding the cellular processes known as epithelial-to-mesenchymal transitions (EMTs), which play a critical role both in normal development and in cancer metastasis. ..
  23. ESTROGEN AND COGNITION OVER THE LIFESPAN
    Thomas Foster; Fiscal Year: 2009
    ..abstract_text> ..
  24. MECHANISMS FOR ALTERED SYNAPTIC FUNCTION DURING AGING
    Thomas Foster; Fiscal Year: 2000
    ..The results of these experiments will add significantly to our knowledge of mechanisms for regulation of synaptic function across the life span and provide a basis for understanding the role of synaptic plasticity in cognitive function. ..
  25. UCLA AIDS Prevention and Treatment Clinical Trials Unit
    Judith Currier; Fiscal Year: 2007
    ..10. Stimulate community involvement and encourage participation of women and racial/ethnic minorities in ACTG, HPTN and VTN clinical trials at the UCLA-APT-CTU. ADMINISTRATIVE COMPONENT: ..
  26. ESTROGEN AND COGNITION OVER THE LIFESPAN
    Thomas Foster; Fiscal Year: 2004
    ..abstract_text> ..
  27. Mechanism for Altered Synaptic Function During Aging
    Thomas Foster; Fiscal Year: 2007
    ..Specifc aim 3 will addresses the issue of how oxidative stress contributes to calcium dysregulation during aging in the hippocampus by examining the influence of redox state on Ca2+ dependent processes. ..
  28. Metabolic Complication of HIV Infection
    Judith Currier; Fiscal Year: 2007
    ..The strong support from my Division Chief and Department Chair to allow me to reduce my clinical and administrative responsibilities will greatly facilitate my success in achieving my goals. ..
  29. Mechanism for Altered Synaptic Function During Aging
    Thomas Foster; Fiscal Year: 2005
    ....
  30. HIV ASSOCIATED NEPHROPATHY IN DRUG ADDICTS
    Pravin Singhal; Fiscal Year: 2007
    ..2. Oxidative stress modulated by drugs accelerates the progression of renal injury in a mouse model of HIVAN. 3. Drugs modulation of the renin-angiotensin system contributes to the progression of renal lesions in mice with HIVAN. ..